Base de dados : MEDLINE
Pesquisa : D06.472.699.327.740.320.580 [Categoria DeCS]
Referências encontradas : 324 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 33 ir para página                         

  1 / 324 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27114332
[Au] Autor:Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
[Ad] Endereço:Fertility Center From A to Z, Ramat Aviv, Israel; IVF Unit, Assuta Medical Center, Rishon Lezion, Israel. Electronic address: barhava@gmail.com.
[Ti] Título:Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
[So] Source:Fertil Steril;106(2):330-3, 2016 Aug.
[Is] ISSN:1556-5653
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To study whether intranasal GnRH agonist (GnRHa) can be effectively used for luteal support in high-responder patients undergoing fresh-embryo transfer after ovulation induction with the use of GnRHa. DESIGN: Retrospective cohort study. SETTING: Private fertility clinic. PATIENT(S): Forty-six high-responder patients were administered a GnRHa ovulation trigger to avoid ovarian hyperstimulation syndrome (OHSS), followed by 2 weeks of daily intranasal GnRHa (nafarelin) for luteal-phase support. No additional progesterone supplementation was administrated. INTERVENTION(S): Intranasal GnRHa for luteal-phase support. MAIN OUTCOME MEASURE(S): The primary outcome was ongoing clinical pregnancy rate. RESULT(S): High median progesterone levels were measured at midluteal phase and on the day of the first positive pregnancy test (190 nmol/L on both measures). We obtained 24 (52.1%) ongoing clinical pregnancies. None of the patients developed OHSS. CONCLUSION(S): Intranasal GnRHa is effective in achieving luteal-phase support in high-responder patients triggered with GnRHa and avoiding OHSS.
[Mh] Termos MeSH primário: Fármacos para a Fertilidade Feminina/administração & dosagem
Hormônio Liberador de Gonadotropina/agonistas
Infertilidade/terapia
Nafarelina/administração & dosagem
Síndrome de Hiperestimulação Ovariana/prevenção & controle
Indução da Ovulação/métodos
Ovulação/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Intranasal
Adulto
Esquema de Medicação
Transferência Embrionária
Feminino
Fármacos para a Fertilidade Feminina/efeitos adversos
Fertilização In Vitro
Hormônio Foliculoestimulante Humano/administração & dosagem
Hormônio Liberador de Gonadotropina/administração & dosagem
Hormônio Liberador de Gonadotropina/análogos & derivados
Hormônio Liberador de Gonadotropina/antagonistas & inibidores
Antagonistas de Hormônios/administração & dosagem
Seres Humanos
Infertilidade/diagnóstico
Infertilidade/fisiopatologia
Menotropinas/administração & dosagem
Nafarelina/efeitos adversos
Recuperação de Oócitos
Síndrome de Hiperestimulação Ovariana/induzido quimicamente
Síndrome de Hiperestimulação Ovariana/fisiopatologia
Indução da Ovulação/efeitos adversos
Gravidez
Taxa de Gravidez
Proteínas Recombinantes/administração & dosagem
Estudos Retrospectivos
Fatores de Risco
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fertility Agents, Female); 0 (Follicle Stimulating Hormone, Human); 0 (Hormone Antagonists); 0 (Recombinant Proteins); 0 (follitropin alfa); 1X0094V6JV (Nafarelin); 33515-09-2 (Gonadotropin-Releasing Hormone); 61489-71-2 (Menotropins); IX503L9WN0 (ganirelix)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170522
[Lr] Data última revisão:
170522
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160427
[St] Status:MEDLINE


  2 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26795496
[Au] Autor:Lahav-Baratz S; Koifman M; Sabo E; Auslender R; Dirnfeld M
[Ad] Endereço:Departments of Obstetrics and Gynecology, IVF Unit, Lady Davis Carmel Medical Center, Haifa, Israel. Electronic address: lahav_shirly@clalit.org.il.
[Ti] Título:p27 and its ubiquitin ligase Skp2 expression in endometrium of IVF patients with repeated hormonal stimulation.
[So] Source:Reprod Biomed Online;32(3):308-15, 2016 Mar.
[Is] ISSN:1472-6491
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:This preliminary study examined a possible effect of long duration repeated hormonal stimulation on the endometrium using a molecular tool. The expression of the hormone stimulated, cell cycle regulators, p27 and its ligase S-phase kinase-interacting protein2 (Skp2), were assessed in 46 endometrial samples of patients who underwent repeated IVF cycles (3-21). Skp2 protein is usually undetectable in normal tissue and can be demonstrated only in rapidly dividing cells. Samples from non-stimulated, normal cycling women served as control group A. Samples of endometrial carcinoma served as control group B. In secretory endometrium, the expression of p27 was found to be lower and Skp2 higher in the study group compared with control group A. Moreover, in 25% of patients of the study group, Skp2 expression was significantly higher (P < 0.05) compared with control group A, reaching concentrations demonstrated in endometrial carcinoma. The findings of this study suggest that repeated hormone stimulation cycles may disrupt endometrial physiology, potentially towards abnormal proliferation. These changes in protein expression are described for the first time in IVF patients and should be further investigated.
[Mh] Termos MeSH primário: Endométrio/efeitos dos fármacos
Indução da Ovulação
Proteínas Quinases Associadas a Fase S/metabolismo
[Mh] Termos MeSH secundário: Adulto
Inibidor de Quinase Dependente de Ciclina p27
Neoplasias do Endométrio/metabolismo
Neoplasias do Endométrio/patologia
Endométrio/metabolismo
Endométrio/patologia
Feminino
Hormônio Foliculoestimulante/efeitos adversos
Hormônio Foliculoestimulante/uso terapêutico
Seres Humanos
Menotropinas/efeitos adversos
Menotropinas/uso terapêutico
Nafarelina/efeitos adversos
Nafarelina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (S-Phase Kinase-Associated Proteins); 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27); 1X0094V6JV (Nafarelin); 61489-71-2 (Menotropins); 9002-68-0 (Follicle Stimulating Hormone)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160123
[St] Status:MEDLINE


  3 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25476811
[Au] Autor:Atkinson P; Koch J; Ledger WL
[Ad] Endereço:Reproductive Medicine Department, Royal Hospital for Women, Sydney, New South Wales, Australia.
[Ti] Título:GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
[So] Source:Aust N Z J Obstet Gynaecol;54(6):581-5, 2014 Dec.
[Is] ISSN:1479-828X
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:AIMS: To analyse the data from all controlled ovarian hyperstimulation antagonist cycles that used an agonist trigger and a freeze-all strategy to quantify the risk of ovarian hyperstimulation syndrome (OHSS) and subsequent pregnancy rates. MATERIALS AND METHODS: A retrospective study of all women attending fertility clinics at IVF Australia, Sydney, undergoing controlled ovarian hyperstimulation (COH) using an antagonist protocol that had a subsequent gonadotropin-releasing hormone (GnRH) agonist trigger and freezing of all oocytes or embryos. The primary outcome measure was to determine the rate of OHSS. The secondary outcome measure was the clinical pregnancy rate. RESULTS: We collected data for 123 women. 25.2% were undergoing oocyte freezing and 74.8% underwent embryo freezing. There were no cases of OHSS, either early or late onset. The pregnancy rate was 31.7% after the first frozen cycle transfer with a cumulative pregnancy rate of 50% after two frozen embryo transfers. CONCLUSION: Our results support the hypothesis that a GnRH agonist trigger and a freeze-all approach prevents OHSS with a good pregnancy rate.
[Mh] Termos MeSH primário: Criopreservação
Embrião de Mamíferos
Fármacos para a Fertilidade Feminina/uso terapêutico
Hormônio Liberador de Gonadotropina/agonistas
Oócitos
Síndrome de Hiperestimulação Ovariana/prevenção & controle
Indução da Ovulação/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Feminino
Fertilização In Vitro
Hormônio Foliculoestimulante/administração & dosagem
Hormônio Liberador de Gonadotropina/antagonistas & inibidores
Seres Humanos
Leuprolida/uso terapêutico
Nafarelina/uso terapêutico
Recuperação de Oócitos
Síndrome de Hiperestimulação Ovariana/induzido quimicamente
Indução da Ovulação/métodos
Gravidez
Taxa de Gravidez
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fertility Agents, Female); 1X0094V6JV (Nafarelin); 33515-09-2 (Gonadotropin-Releasing Hormone); 9002-68-0 (Follicle Stimulating Hormone); EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:141205
[Lr] Data última revisão:
141205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141206
[St] Status:MEDLINE
[do] DOI:10.1111/ajo.12277


  4 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24188873
[Au] Autor:Sunkara SK; Coomarasamy A; Faris R; Braude P; Khalaf Y
[Ad] Endereço:Assisted Conception Unit, Guy's and St. Thomas' Foundation Trust, King's College London, United Kingdom. Electronic address: sksunkara@hotmail.com.
[Ti] Título:Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial.
[So] Source:Fertil Steril;101(1):147-53, 2014 Jan.
[Is] ISSN:1556-5653
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To compare the efficacy of the long GnRH agonist vs. the short GnRH agonist vs. the GnRH antagonist regimens in poor responders undergoing IVF. DESIGN: Randomized controlled trial. SETTING: Tertiary referral fertility units. PATIENT(S): Women with previous poor ovarian response undergoing IVF. INTERVENTION(S): One hundred eleven women were randomized to the long GnRH agonist, short agonist, and antagonist regimens. MAIN OUTCOME MEASURE(S): The primary outcome was the number of oocytes retrieved. Secondary outcome measures were gonadotropin consumption, duration of stimulation, cycle cancellation rate, mature oocytes retrieved, fertilization rate, cycles reaching ET, and clinical and ongoing pregnancy rates. RESULT(S): Number of oocytes retrieved was significantly higher with long GnRH agonist compared with the short agonist regimen (4.42 ± 3.06 vs. 2.71 ± 1.60), while there was no significant difference between long agonist and antagonist regimens (4.42 ± 3.06 vs. 3.30 ± 2.91). Duration of stimulation and total gonadotropin dose were significantly higher with long agonist compared with short agonist and antagonist regimens. The ongoing pregnancy rate was 8.1% with long and short agonist regimens and 16.2% with the antagonist regimen. CONCLUSION(S): Long GnRH agonist and antagonist regimens offer a suitable choice for poor responders, whereas the short agonist regimen may be less effective because of fewer eggs retrieved.
[Mh] Termos MeSH primário: Fármacos para a Fertilidade Feminina/administração & dosagem
Fertilização In Vitro/métodos
Hormônio Liberador de Gonadotropina/agonistas
Hormônio Liberador de Gonadotropina/antagonistas & inibidores
[Mh] Termos MeSH secundário: Adulto
Feminino
Hormônio Liberador de Gonadotropina/sangue
Gonadotropinas/administração & dosagem
Seres Humanos
Nafarelina/administração & dosagem
Gravidez
Taxa de Gravidez/tendências
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Fertility Agents, Female); 0 (Gonadotropins); 1X0094V6JV (Nafarelin); 33515-09-2 (Gonadotropin-Releasing Hormone)
[Em] Mês de entrada:1402
[Cu] Atualização por classe:140708
[Lr] Data última revisão:
140708
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131106
[St] Status:MEDLINE


  5 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23931964
[Au] Autor:Huber M; Hadziosmanovic N; Berglund L; Holte J
[Ad] Endereço:Department of Obstetrics and Gynecology, Östersunds Sjukhus, Östersund, Sweden.
[Ti] Título:Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem.
[So] Source:Fertil Steril;100(5):1270-6, 2013 Nov.
[Is] ISSN:1556-5653
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To explore the utility of using the ratio between oocyte yield and total dose of FSH, i.e., the ovarian sensitivity index (OSI), to define ovarian response patterns. DESIGN: Retrospective cross-sectional study. SETTING: University-affiliated private center. PATIENT(S): The entire unselected cohort of 7,520 IVF/intracytoplasmic sperm injection treatments (oocyte pick-ups [OPUs]) during an 8-year period (long GnRH agonist-recombinant FSH protocol). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): The distribution of the OSI (oocytes recovered × 1,000/total dose of FSH), the cutoff levels for poor and high response, set at ±1 SD, and the relationship between OSI and treatment outcome. RESULT(S): OSI showed a log-normal distribution with cutoff levels for poor and high response at 1.697/IU and 10.07/IU, respectively. A nomogram is presented. Live-birth rates per OPU were 10.5 ± 0.1%, 26.9 ± 0.6%, and 36.0 ± 1.4% for poor, normal, and high response treatments, respectively. The predictive power (C-statistic) for OSI to predict live birth was superior to that of oocyte yield. CONCLUSION(S): The OSI improves the definition of ovarian response patterns because it takes into account the degree of stimulation. The nomogram presents evidence-based cutoff levels for poor, normal, and high response and could be used for unifying study designs involving ovarian response patterns.
[Mh] Termos MeSH primário: Fármacos para a Fertilidade Feminina/administração & dosagem
Hormônio Foliculoestimulante Humano/administração & dosagem
Hormônio Liberador de Gonadotropina/agonistas
Recuperação de Oócitos
Ovário/efeitos dos fármacos
Indução da Ovulação/métodos
Ovulação/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Busserrelina/administração & dosagem
Gonadotropina Coriônica/administração & dosagem
Estudos Transversais
Esquema de Medicação
Quimioterapia Combinada
Feminino
Fármacos para a Fertilidade Feminina/efeitos adversos
Fertilização In Vitro
Hormônio Foliculoestimulante Humano/efeitos adversos
Hormônio Liberador de Gonadotropina/metabolismo
Seres Humanos
Nascimento Vivo
Modelos Logísticos
Nafarelina/administração & dosagem
Nomogramas
Síndrome de Hiperestimulação Ovariana/induzido quimicamente
Síndrome de Hiperestimulação Ovariana/fisiopatologia
Ovário/metabolismo
Ovário/fisiopatologia
Gravidez
Taxa de Gravidez
Proteínas Recombinantes/administração & dosagem
Estudos Retrospectivos
Fatores de Risco
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 0 (Fertility Agents, Female); 0 (Follicle Stimulating Hormone, Human); 0 (Recombinant Proteins); 1X0094V6JV (Nafarelin); 33515-09-2 (Gonadotropin-Releasing Hormone); PXW8U3YXDV (Buserelin)
[Em] Mês de entrada:1312
[Cu] Atualização por classe:131104
[Lr] Data última revisão:
131104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130813
[St] Status:MEDLINE


  6 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23774185
[Au] Autor:Kolakovic R; Peltonen L; Laukkanen A; Hellman M; Laaksonen P; Linder MB; Hirvonen J; Laaksonen T
[Ad] Endereço:Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. Electronic address: ruzica.kolakovic@helsinki.fi.
[Ti] Título:Evaluation of drug interactions with nanofibrillar cellulose.
[So] Source:Eur J Pharm Biopharm;85(3 Pt B):1238-44, 2013 Nov.
[Is] ISSN:1873-3441
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Nanofibrillar cellulose (NFC) (also referred to as cellulose nanofibers, nanocellulose, microfibrillated, or nanofibrillated cellulose) has recently gotten wide attention in various research areas and it has also been studied as excipient in formulation of the pharmaceutical dosage forms. Here, we have evaluated the interactions between NFC and the model drugs of different structural characteristics (size, charge, etc.). The series of permeation studies were utilized to evaluate the ability of the drugs in solution to diffuse through the thin, porous, dry NFC films. An incubation method was used to determine capacity of binding of chosen model drugs to NFC as well as isothermal titration calorimetry (ITC) to study thermodynamics of the binding process. A genetically engineered fusion protein carrying double cellulose binding domain was used as a positive control since its affinity and capacity of binding for NFC have already been reported. The permeation studies revealed the size dependent diffusion rate of the model drugs through the NFC films. The results of both binding and ITC studies showed that the studied drugs bind to the NFC material and indicated the pH dependence of the binding and electrostatic forces as the main mechanism.
[Mh] Termos MeSH primário: Celulose/química
Química Farmacêutica/métodos
Nanofibras/química
[Mh] Termos MeSH secundário: Administração Oral
Calorimetria
Difusão
Interações Medicamentosas
Excipientes
Concentração de Íons de Hidrogênio
Microscopia Eletrônica de Varredura
Muramidase/química
Nafarelina/química
Porosidade
Ligação Proteica
Estrutura Terciária de Proteína
Proteínas Recombinantes de Fusão/química
Proteínas Recombinantes/química
Solubilidade
Eletricidade Estática
Propriedades de Superfície
Termodinâmica
Xilanos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Excipients); 0 (Recombinant Fusion Proteins); 0 (Recombinant Proteins); 0 (Xylans); 1X0094V6JV (Nafarelin); 9004-34-6 (Cellulose); EC 3.2.1.17 (Muramidase)
[Em] Mês de entrada:1408
[Cu] Atualização por classe:131204
[Lr] Data última revisão:
131204
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130619
[St] Status:MEDLINE


  7 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23635751
[Au] Autor:Gatti J; Brinker A; Avigan M
[Ti] Título:Spontaneous reports of seizure in association with leuprolide (lupron depot), goserelin (zoladex implant), and naferelin (synarel nasal spray).
[So] Source:Obstet Gynecol;121(5):1107, 2013 May.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Antineoplásicos Hormonais/efeitos adversos
Fármacos para a Fertilidade Feminina/efeitos adversos
Gosserrelina/efeitos adversos
Leuprolida/efeitos adversos
Nafarelina/efeitos adversos
Convulsões/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Preparações de Ação Retardada
Feminino
Seres Humanos
Sprays Nasais
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0 (Delayed-Action Preparations); 0 (Fertility Agents, Female); 0 (Nasal Sprays); 0F65R8P09N (Goserelin); 1X0094V6JV (Nafarelin); EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1307
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:130503
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0b013e31828c9cb3


  8 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23206386
[Au] Autor:Röblitz S; Stötzel C; Deuflhard P; Jones HM; Azulay DO; van der Graaf PH; Martin SW
[Ad] Endereço:Computational Systems Biology Group, Zuse Institute Berlin (ZIB), Berlin, Germany. susanna.roeblitz@zib.de
[Ti] Título:A mathematical model of the human menstrual cycle for the administration of GnRH analogues.
[So] Source:J Theor Biol;321:8-27, 2013 Mar 21.
[Is] ISSN:1095-8541
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The paper presents a differential equation model for the feedback mechanisms between gonadotropin-releasing hormone (GnRH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), development of follicles and corpus luteum, and the production of estradiol (E2), progesterone (P4), inhibin A (IhA), and inhibin B (IhB) during the female menstrual cycle. Compared to earlier human cycle models, there are three important differences: The model presented here (a) does not involve any delay equations, (b) is based on a deterministic modeling of the GnRH pulse pattern, and (c) contains less differential equations and less parameters. These differences allow for a faster simulation and parameter identification. The focus is on modeling GnRH-receptor binding, in particular, by inclusion of a pharmacokinetic/pharmacodynamic (PK/PD) model for a GnRH agonist, Nafarelin, and a GnRH antagonist, Cetrorelix, into the menstrual cycle model. The final mathematical model describes the hormone profiles (LH, FSH, P4, E2) throughout the menstrual cycle of 12 healthy women. It correctly predicts hormonal changes following single and multiple dose administration of Nafarelin or Cetrorelix at different stages in the cycle.
[Mh] Termos MeSH primário: Hormônio Liberador de Gonadotropina/análogos & derivados
Ciclo Menstrual/fisiologia
[Mh] Termos MeSH secundário: Disponibilidade Biológica
Membrana Celular/metabolismo
Simulação por Computador
Corpo Lúteo/metabolismo
Feminino
Hormônio Foliculoestimulante/sangue
Hormônio Liberador de Gonadotropina/administração & dosagem
Hormônio Liberador de Gonadotropina/farmacocinética
Seres Humanos
Hormônio Luteinizante/sangue
Modelos Biológicos
Nafarelina/administração & dosagem
Nafarelina/farmacocinética
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
1X0094V6JV (Nafarelin); 33515-09-2 (Gonadotropin-Releasing Hormone); 9002-67-9 (Luteinizing Hormone); 9002-68-0 (Follicle Stimulating Hormone); OON1HFZ4BA (cetrorelix)
[Em] Mês de entrada:1309
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121205
[St] Status:MEDLINE


  9 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23053053
[Au] Autor:Gentil M; Hoffmann B; Spang A; Failing K; Goericke-Pesch S
[Ad] Endereço:Clinic for Obstetrics, Gynecology and Andrology of Large and Small Animals, Justus-Liebig-University Giessen, Germany. schulzmichaela@gmx.de
[Ti] Título:Restart of steroidogenesis in dogs during recrudescence of testicular function following downregulation with a GnRH-agonist implant.
[So] Source:Cell Tissue Res;350(3):513-23, 2012 Dec.
[Is] ISSN:1432-0878
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:To date, no details are available concerning the restart of steroidogenesis following the downregulation of testicular endocrine and germinative function by gonadotrophin-releasing hormone (GnRH)-agonist implants. This restart was assessed by determining the expression of steroidogenic acute regulatory (StAR) protein, cytochrome P450 side-chain cleavage enzyme (P450scc) and cytochrome P450 17α-hydroxylase,17,20-lyase (P450c17). The re-establishment of steroidogenesis was initiated by the removal of the GnRH-agonist implant (18.5 mg azagly nafarelin, Gonazon) at 5 months after treatment. Testes were removed at 3-week intervals (weeks 0-24) and four groups were formed according to the stage of spermatogenesis as revealed by the most developed germ cells observed (developmental group [DG] spermatocytes to DG elongated spermatids). Five dogs served as untreated controls. Positive immunostaining for StAR, P450scc and P450c17 was restricted to Leydig cells. Western blot indicated the specifity of the respective antibodies with hints of a expression of canine-specific P450scc and P450c17 proteins. A significant effect of group was observed for a percentage of the immunopositive area (PIA) as an indicator of active Leydig cells for StAR (P<0.05), P450scc (P<0.001) and P450c17 (P<0.001), with PIA being lowest for the DG spermatocytes. With regard to the strength of the immunopositive signal, a significant effect of group was found for P450scc (P<0.01) and P450c17 (P<0.05), with the lowest intensity being observed in DG spermatocytes. At the mRNA level, the upregulation from DG spermatocytes to DG round spermatids was clearly evident but was only significant for P450scc (P<0.05). Thus, downregulation affects the whole cascade of steroidogenesis, whereas withdrawal of inhibition results in a rapid restart, in part indicating a rebound phenomenon.
[Mh] Termos MeSH primário: Enzima de Clivagem da Cadeia Lateral do Colesterol/biossíntese
Hormônio Liberador de Gonadotropina/agonistas
Nafarelina/análogos & derivados
Fosfoproteínas/biossíntese
Esteroide 17-alfa-Hidroxilase/biossíntese
Esteroides/biossíntese
Testículo/fisiologia
[Mh] Termos MeSH secundário: Animais
Enzima de Clivagem da Cadeia Lateral do Colesterol/genética
Cães
Regulação para Baixo/efeitos dos fármacos
Implantes de Medicamento
Hormônio Liberador de Gonadotropina/genética
Hormônio Liberador de Gonadotropina/metabolismo
Masculino
Nafarelina/administração & dosagem
Fosfoproteínas/genética
RNA Mensageiro/biossíntese
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Esteroide 17-alfa-Hidroxilase/genética
Testículo/efeitos dos fármacos
Testículo/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Implants); 0 (Phosphoproteins); 0 (RNA, Messenger); 0 (Steroids); 0 (azaglycylnafarelin); 0 (steroidogenic acute regulatory protein); 1X0094V6JV (Nafarelin); 33515-09-2 (Gonadotropin-Releasing Hormone); EC 1.14.14.19 (Steroid 17-alpha-Hydroxylase); EC 1.14.15.6 (Cholesterol Side-Chain Cleavage Enzyme)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121012
[St] Status:MEDLINE
[do] DOI:10.1007/s00441-012-1506-5


  10 / 324 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22050326
[Au] Autor:Goericke-Pesch S; Ludwig C; Hoffmann B
[Ad] Endereço:Clinic for Obstetrics, Gynecology and Andrology of Large and Small Animals, Justus-Liebig-University, Giessen, Germany. Sandra.Pesch@vetmed.uni-giessen.de
[Ti] Título:Development of semen quality following reversible downregulation of testicular function in male dogs with a GnRH agonist implant.
[So] Source:Reprod Domest Anim;47(4):625-8, 2012 Aug.
[Is] ISSN:1439-0531
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Slow-release GnRH agonist implants have shown to be an effective and reversible alternative to surgical castration. Testicular function is downregulated with an arrest of spermatogenesis on the level of spermatogonia/primary spermatocytes but is fully restored after abolition of downregulation. Aim of this study was to assess the quality of ejaculates after active abolishment of downregulation by implant removal and to follow recrudescence of spermatogenesis. Five dogs - which served as their own controls - were treated with a slow-release implant containing the GnRH agonist azagly-nafarelin. Implants were removed during full downregulation (testosterone <0.1 ng/ml), and attempts to collect ejaculates started from week 4 onwards to week 29. First ejaculates could be obtained between weeks 8 and 12 with the first fully elongated spermatozoa observed in week 10. Volume, %motility and total sperm count increased and %pathomorphology decreased during the course of the study with all ejaculates being in the normal range by week 29. Our data indicate that onset of recrudescence of spermatogenesis coincides with the first testosterone increase after active abolishment of downregulation. Semen quality was fully regained with a significant improvement of %pathomorphology (p < 0.05) and a tendency of improved %motility. However, these observations on an improved semen quality need further validation and no final conclusions can be drawn yet.
[Mh] Termos MeSH primário: Cães
Hormônio Liberador de Gonadotropina/agonistas
Nafarelina/análogos & derivados
Sêmen/fisiologia
Testículo/efeitos dos fármacos
Testículo/fisiologia
[Mh] Termos MeSH secundário: Animais
Implantes de Medicamento
Masculino
Nafarelina/administração & dosagem
Orquiectomia/métodos
Orquiectomia/veterinária
Análise do Sêmen/veterinária
Contagem de Espermatozoides/veterinária
Motilidade Espermática
Espermatogênese
Espermatozoides
Testosterona/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Implants); 0 (azaglycylnafarelin); 1X0094V6JV (Nafarelin); 33515-09-2 (Gonadotropin-Releasing Hormone); 3XMK78S47O (Testosterone)
[Em] Mês de entrada:1211
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111105
[St] Status:MEDLINE
[do] DOI:10.1111/j.1439-0531.2011.01933.x



página 1 de 33 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde